Halozyme Therapeutics (HALO)
Enables subcutaneous delivery of partner medicines through ENHANZE technology.
Something off on this page? Send us feedback.
Provides ENHANZE, a drug-delivery platform that helps partners convert injectable medicines from intravenous to subcutaneous administration. Collaboration revenue, product sales, and royalties are supported by ENHANZE, Hylenex, auto-injector technologies, and newer Hypercon and Surf Bio delivery assets.
Turns injectable medicines and fluids into subcutaneous treatments through ENHANZE, an rHuPH20-based delivery technology. Pharmaceutical and biotechnology partners combine ENHANZE with their own compounds, while Halozyme earns collaboration revenue, product sales, and royalties.
The delivery portfolio also includes Hylenex, auto-injector technologies acquired with Antares Pharma, and the Hypercon and Surf Bio technologies. ENHANZE-enabled products are commercialized in more than 100 markets, linking the business to global partner programs.
The company reports one operating segment covering proprietary enzymes and devices. Its model depends on partner development and commercialization, continued access to patent and other proprietary rights, and the ability to license delivery technologies amid alternative subcutaneous approaches.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 10, 2026 | Wells Fargo | Target | Target: $75 | Target: $95 |
| Aug 7, 2026 | Morgan Stanley | Reiterate | Rating: —Target: $93 | Target: $105 |
| Aug 7, 2026 | Leerink Partners | Upgrade | Target: $70 | Target: $110 |
| Aug 7, 2026 | H.C. Wainwright | Reiterate | Rating: —Target: $95 | Target: $115 |
| Jun 3, 2026 | UBS | Target | Target: $56 | Target: $90 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $231.0M · Total debt $2.15B · Total assets $2.58B · Shareholders' equity $143.5M
- Revenue
- $481.0M
- Operating income
- $287.7M
- Net income
- $229.9M
No dividends on record.
| Institutions | ≈ 109.17% | 123.90M shares | |
|---|---|---|---|
| 688 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 1.26% | 1.43M shares | |
| 14 holders · as of Sep 17, 2026 | |||
| Adds to | 110.43% | ||
113.50M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 110.43%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 11.69% | 13.27M | as of Jun 30, 2026 |
Artisan Partners Limited PartnershipInstitution | 8.38% | 9.51M | filed Feb 4, 2022 |
Vanguard Capital Management LLCInstitution | 4.71% | 5.35M | as of Jun 30, 2026 |
Vanguard Portfolio Management LLCInstitution | 4.67% | 5.30M | as of Jun 30, 2026 |
State Street CorpInstitution | 4.56% | 5.18M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 16, 2026 | Matthew L. Posard | director | −18,996 | $107.74 |
| Sep 11, 2026 | Helen Torley | director, officer: PRESIDENT AND CEO | −20,000 | $107.24 |
| Sep 10, 2026 | Helen Torley | director, officer: PRESIDENT AND CEO | −20,000 | $107.17 |
| Sep 9, 2026 | Helen Torley | director, officer: PRESIDENT AND CEO | −20,000 | $107.43 |
| Aug 19, 2026 | Helen Torley | director, officer: PRESIDENT AND CEO | −20,000 | $107.00 |
- West Pharmaceutical Services
On-body self-injection systems for high-volume SC biologics
- BD
Wearable SC delivery systems for complex biologics
- Amphastar Pharmaceuticals
Bovine hyaluronidase alternative to Hylenex recombinant
- Xeris Biopharma
Ultra-concentrated, small-volume SC formulation technology
- Stevanato Group
Autoinjector and on-body delivery platforms for pharma partners
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Halozyme Therapeutics | $113.03 | −1.82% | $13.66B | 34.4 | 11.8 | 8.2 | +47.7% |
| West Pharmaceutical Services | $370.66 | −0.12% | $26.12B | 47.5 | 40.0 | 7.9 | +13.9% |
| BD | $182.90 | −0.06% | $50.42B | 55.1 | 13.8 | 2.4 | −9.6% |
| Amphastar Pharmaceuticals | $24.33 | +0.04% | $1.07B | 14.4 | 7.6 | 1.5 | +5.4% |
| Xeris Biopharma | $8.79 | +0.69% | $1.51B | — | 47.2 | 4.5 | +27.2% |
| Stevanato Group | $21.09 | −2.81% | $5.92B | 39.6 | 27.1 | 4.2 | +4.6% |
| Median | 43.5 | 27.1 | 4.2 | +5.4% |